ALL Brexucabtagene autoleucel IND Dasatinib G Obecabtagene autoleucel Ponatinib IND AML / MDS Azacitidine Cytarabine / daunorubicin (liposomaal) Decitabine/cedazuridine Eprenetapopt Glasdegib Imetelstat Iomab-B Venetoclax IND Aggressive non-Hodgkin’s lymphoma Axicabtagene ciloleucel IND Crizotinib IND Ibrutinib Mantle cell lymphoma (MCL), 1L. IND Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation Lisocabtagene maraleucel Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib IND CLL Acalabrutinib Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Duvelisib Ibrutinib IND Pirtobrutinib IND Ublituximab Zanubrutinib Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy IND CML Asciminib Indolent non-Hodgkin’s lymphoma Axicabtagene ciloleucel IND Copanlisib Hypericin Lacutamab Mosunetuzumab Parsaclisib Umbralisib Multiple Myeloma Belantamab mafodotin IND Carfilzomib IND Ciltacabtagene autoleucel Daratumumab Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. IND Smouldering multipel myeloom. IND Elranatamab Idecabtagene vicleucel Isatuximab Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. IND Ixazomib IND Melphalan flufenamide IND Pomalidomide IND Selinexor IND Teclistimab Thalidomide G Venetoclax IND Zevorcabtagene autoleucel Myeloproliferative disorders Momelotinib Navitoclax Ropeginterferon alfa-2b Other hematology Eltrombopag IND Zanubrutinib Stem cell transplants Brexucabtagene autoleucel Inolimomab Motixafortide Omidubicel Ruxolitinib IND Tabelecleucel Tisagenlecleucel-T IND Unknown Axicabtagene ciloleucel IND